Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672438 · ClinicalTrials.gov registry record · NA
Heritability of Opioid Effects: A Twin Study
A NA study, sponsored by Martin Angst.
- Completed
- Registry status
- NA
- Development phase
- 242
- Enrollment target
NCT00672438: Completed NA study, sponsored by Martin Angst.
NCT00672438 is a NA study that has completed, run by Martin Angst. The registered enrollment target is 242 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00672438, a NA study, has completed, sponsored by Martin Angst.
- COMPLETED
- Registry status
- NA
- Development phase
- 242 participants
- Enrollment target
Study Summary
Proposed twin study will test to what degree inter-individual differences in pain sensitivity and amount of pain relief in response to opioid therapy are inherited or alternatively, are due to environmental factors. This knowledge is important to guide future studies trying to explain such inter-individual differences. For example, finding that differences are largely due to environmental factors would discourage genomic studies and emphasize epidemiological studies.
Primary Outcome
Degrees Centigrade Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin at the volar forearm. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature.
Interventions
- DRUG Alfentanil
- OTHER Saline placebo infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-06 |
| Phase | NA |
What the finished NCT00672438 record still lists
NCT00672438 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Alfentanil is the first listed.
NCT00672438 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00672438 about?
NCT00672438 is a clinical study titled "Heritability of Opioid Effects: A Twin Study". Proposed twin study will test to what degree inter-individual differences in pain sensitivity and amount of pain relief in response to opioid therapy are inherited or alternatively, are due to environmental factors. This knowledge is important to guide future studies trying to explain such inter-ind...
What is the current status of trial NCT00672438?
This trial is currently completed. It is a NA study. The enrollment target is 242 participants. The study started on 2008-05. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00672438?
The interventions under investigation include: Alfentanil (DRUG), Saline placebo infusion (OTHER).
Who is sponsoring clinical trial NCT00672438?
This trial is sponsored by Martin Angst, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00672438's enrollment target sits among peer trials
242 439th of 2000 higher than 1,561 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia